Publications

Healthcare resource use and costs following catheter ablation in paroxysmal supraventricular tachycardia (PSVT) patients age <65

Sacks NC, Cyr PL, Green S, Wood D, Pokorney S. Healthcare resource use and costs following catheter ablation in paroxysmal supraventricular tachycardia (PSVT) patients age <65. Podium presentation, International Society for Pharmacoeconomics and Outcomes Research. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, May 2019.

Clinical burden of recurrent clostridioides difficile infection: A real-world data analysis

Stong L, Nelson WW, Feuerstadt P, Boules M, Sacks NC, Portelli A, Healey B, Lang K, Dahdal DN. Clinical burden of recurrent clostridioides difficile infection: A real-world data analysis. American College of Gastroenterology annual meeting, San Antonio, TS, October 2019.

Prevalence of patients with paroxysmal supraventricular tachycardia (PSVT) in the United States

Sacks NC, Cyr PL, Green S, Healey B, Preib M, Wood D, Pokorney S. Prevalence of patients with paroxysmal supraventricular tachycardia (PSVT) in the United States. Poster presentation, European Society for Cardiology Congress, Paris, France, September 2019.

Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States

Sacks NC, Everson K, Cyr PL, Preib M, Wood D, Pokorney S. Healthcare resource use and expenditures in patients newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States. Podium presentation, International Society for Pharmacoepidemiology Annual Meetings, Philadelphia, PA, August 2019.

Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US

Hathway J, Jensen IS, Cyr PL, Koshy, TI, Parks, P, Weinstein MC. Economic analysis of colorectal cancer screening from multiple stakeholder perspectives: Key components to improve practical applications in the US. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Variations in healthcare resource use and expenditures by age in patients under Age 65 newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States

Sacks NC, Everson K, Cyr PL, Emden M, Preib M, Wood D, Pokorney S. Variations in healthcare resource use and expenditures by age in patients under Age 65 newly diagnosed with paroxysmal supraventricular tachycardia (PSVT) in the United States. ISPOR 24th Annual International Meeting, New Orleans LA, 2019.

Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients

Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019.

Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study

Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks NC, Cyr PL, Taylor S. 2019. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study. Clin Therapeut 41(2):303–313; doi: 10.1016/j.clinthera.2018.12.014.

Budget impact analysis of using daunarubicin-cytarabine liposome in patients with newly diagnosed therapy-related AML or AML and myelodysplasia-related changes

Evaluating clinical and economic burden of paroxysmal supraventricular tachycardia (PSVT) using real world evidence

Sacks NC. Evaluating clinical and economic burden of paroxysmal supraventricular tachycardia (PSVT) using real world evidence. Podium presentation, Real World Data and Life Science Analytics Congress. Boston, MA, October 2018.

Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.

Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy. ISPOR 23^rd Annual Conference, Baltimore MD, 2018.

Healthcare resource use and expenditures in patients under 65 years of age and newly diagnosed with paroxysmal superventricular tachycardia (PSVT) in the United States

Sacks NC, Cyr PL, Bariahtaris S, Sharma A, Everson K, Douville P, Ruskin J. Healthcare resource use and expenditures in patients under 65 years of age and newly diagnosed with paroxysmal superventricular tachycardia (PSVT) in the United States. Podium Presentation at World Congress on Heart Disease, Boston MA, 2018.

Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention (PCI) patients: A US hospital perspective

Jensen IS, Wu E, Cyr PL, Claussen M, Winkler T, Salhuddin K, Prats J, et al. Cost-consequence analysis of using cangrelor in high angiographic risk percutaneous coronary intervention (PCI) patients: A US hospital perspective. Transcatheter Cardiovascular Therapeutics (TCT), San Diego, CA, 2018.

A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL)

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of Axicabtagene Ciloleucil in a US population of patients with relapsed/refractory large B-cell lymphoma (RR-LBCL). European Blood and Marrow Transplantation Meeting, Lisbon Portugal, 2018.

A budget impact model of axicabtagene ciloleucel (Axi-cel) in an US population of patients with relapsed or refractory large b-cell lymphoma (RR-LBCL)

Hathway J, Purdum AG, Lin VW, Cyr PL, Westin J, Jensen IS. A budget impact model of axicabtagene ciloleucel (Axi-cel) in an US population of patients with relapsed or refractory large b-cell lymphoma (RR-LBCL). Podium presentation at ISPOR 23th Annual International Meeting, Baltimore MD, 2018.

Estimating the life-time indirect costs of vision impairment (VI) in inherited retinal degeneration (IRD): Economic impact on education, government benefit programs, productivity and tax loss for patients and caregiver burden

Jensen I, Zacherle E, Noone J, Blanchette C, Kay C. Estimating the life-time indirect costs of vision impairment (VI) in inherited retinal degeneration (IRD): Economic impact on education, government benefit programs, productivity and tax loss for patients and caregiver burden. Presented at AAO 2018.

Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set

Sacks NC, Cyr PL, Louie AC, Liu Y, Chiarella MT, Sharma A, Chung KC. 2018. Burden of acute myeloid leukemia among older, newly diagnosed patients: Retrospective analysis of data from the 2010-2012 Medicare limited data set. Clin Ther 40(5):692–703.e2; doi: 10.1016/j.clinthera.2018.03.012.

Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs

Wu E, Jensen IS, Cyr PL, Kisner H. Economic model shows that guideline recommended testing of patients with early symptoms of myeloma results in improved patient outcomes and decreased hospital costs. American Society of Hematology, Atlanta GA, 2017.

Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.